References
- Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113(4):775–783.
- Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152.
- Acute myeloid leukemia – cancer stat facts. SEER [cited 22 Sep 2020]. Available from: https://seer.cancer.gov/statfacts/html/amyl.html
- National comprehensive cancer network. Acute myeloid leukemia (version 2.2021). Available from: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
- Losman J-A, Kaelin WG. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27(8):836–852.
- Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553–567.
- Luesink M, Jansen JH. Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia. Br J Haematol. 2010;151(3):209–220.
- Luesink M, Pennings JLA, Wissink WM, et al. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood. 2009;114(27):5512–5521.
- Fathi AT, DiNardo CD, Kline I, et al. Differentiation syndrome associated with Enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1/2 study. JAMA Oncol. 2018;4(8):1106–1110.
- Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–731.
- DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML . N Engl J Med. 2018;378(25):2386–2398.
- Norsworthy KJ, Mulkey F, Scott EC, et al. Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration Systematic Analysis. Clin Cancer Res. 2020;26(16):4280–4288.
- Center for drug evaluation and research. FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib). FDA. Published online December 20, 2019 [cited 14 Dec 2020]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-symptoms-serious-condition-affecting-blood-cells-are-not-being-recognized-leukemia
- Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support . J Biomed Inform. 2009;42(2):377–381.
- Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
- Tibsovo [package insert]. Cambridge, MA: Agios Pharmaceuticals, Inc.; 2019 [cited 14 Dec 2020]. Available from: https://www.tibsovopro.com/pdf/prescribinginformation.pdf
- Idhifa [package insert]. Summit, NJ: Celgene Corporation; 2020.